CRISPR Therapeutics AG

CRSP has broken decisively below its key horizontal support zone and 9/20 EMAs, confirming a medium-term bearish phase. Short-term momentum remains negative with price extended below EMAs and no signs of exhaustion. We will execute Sell Now on continued weakness, viewing any rally into the broken support zone as an opportunity to reinforce positions to the downside.

• ↑Q2 CASGEVY sales $76M (+151% YoY) drives strong growth.
• ↑Q2 revenue $10.2M vs $7M consensus; beat expectations.
• ↓Q2 loss of $0.94/sh vs $1.10 estimate highlights ongoing deficits.